Brand Name

Aczone

Generic Name
Dapsone
View Brand Information
FDA approval date: June 24, 2009
Classification: Sulfone
Form: Tablet, Gel

What is Aczone (Dapsone)?

Dapsone gel, 5%, is indicated for the topical treatment of acne vulgaris. Dapsone gel, 5% is indicated for the topical treatment of acne vulgaris.

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid
Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid
Who is this study for: Patients with Mucous Membrane Pemphigoid
Enrollment Status: Recruiting
Publish Date: February 18, 2026
Intervention Type: Drug
Study Drugs: Rituximab, Cyclophosphamide
Study Phase: Phase 3

Summary: Mucous membrane pemphigoid (MMP) describes a group of chronic auto-immune bullous diseases (AIBD) of the basement membrane zone (BMZ), characterized by predominant or exclusive mucosal involvement, including oral, naso-pharyngeal, laryngo-tracheal, genital, oesophageal, anal and ocular mucous membranes. Circulating autoantibodies are directed against various antigens of the BMZ: BP180, laminin 332...

A Randomized Multicenter Study for Isolated Skin Vasculitis
A Randomized Multicenter Study for Isolated Skin Vasculitis
Who is this study for: Adult patients with Skin Vasculitis
Enrollment Status: Recruiting
Publish Date: January 23, 2026
Intervention Type: Drug
Study Drugs: Colchicine, Dapsone, Azathioprine
Study Phase: Phase 2

Summary: Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis.

Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical Trial
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical Trial
Enrollment Status: Recruiting
Publish Date: February 11, 2025
Intervention Type: Drug
Study Phase: Not Applicable

Summary: Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves...

View All Clinical Trials

Related Latest Advances

Clinical characteristics, associated comorbidities, and treatment approaches in pyoderma gangrenosum: a single-center retrospective analysis.
Clinical characteristics, associated comorbidities, and treatment approaches in pyoderma gangrenosum: a single-center retrospective analysis.
Journal: Acta dermatovenerologica Alpina, Pannonica, et Adriatica
Published: March 31, 2026
Recommendations from the Clinical Toxicology Recommendations Collaborative on the administration of activated charcoal in acute oral overdose.
Recommendations from the Clinical Toxicology Recommendations Collaborative on the administration of activated charcoal in acute oral overdose.
Journal: Clinical toxicology (Philadelphia, Pa.)
Published: March 30, 2026
A 10-year retrospective study of patients with acquired methemoglobinemia: causative agents, clinical characteristics, and outcomes.
A 10-year retrospective study of patients with acquired methemoglobinemia: causative agents, clinical characteristics, and outcomes.
Journal: Clinical toxicology (Philadelphia, Pa.)
Published: March 23, 2026
View All Latest Advances